Introduction
Manual auscultatory blood pressure (BP) measurement, in which an observer listens for Korotkoff sounds, is still widely regarded as the most accurate procedure, despite the acknowledged influence of observer errors 1 and equipment criticism. [2] [3] [4] It has distinct advantages in sub-populations in which automated oscillometric device readings are less accurate, particularly for those with conditions such as diabetes, 5 arrhythmias, 6 pre-eclampsia 7 and for the elderly. 8 Since its proposal in 2001, various hybrid devices 9, 10 have been manufactured and validated. These devices provide a mercury-free, electronic pressure display that enables manual auscultatory BP measurement through the simulation of an aneroid display (Accoson Green-light, 11 A.C. Cossor & son Ltd., Essex, UK), a falling mercury column (A&D UM-101, 12 A&D Company Ltd., Tokyo, Japan), or a large numeric digital LCD (liquid crystal display) (Rossmax Mandaus II, Rossmax International Ltd., Taipei, Taiwan, 13 PMS Mandaus, 14 PMS Instruments Ltd., Berkshire, UK).
In addition, the PMS Mandaus 14 and A&D UM-101 12 devices also have a blinded auscultatory function, whereby the operator/observer presses a button during cuff deflation on hearing the appearance (systolic) and disappearance (diastolic) of Korotkoff sounds. The theoretical advantages of this technique, such as eliminating observer bias and terminal digit preference, make it particularly relevant to the clinical trials environment. However, it was found to underestimate BP, because of the delayed reaction and recognition time on identifying BP. 12 The Nissei DM-3000 (Japan Precision Instruments, Gunma, Japan) is a fully automated, upper arm, hybrid sphygmomanometer. It has a backlit graphic bar display similar to a 300-mm mercury column (graduated in 2-mm steps) for manual measurements, as well as a numeric LCD display for the automated measurement result display. During a manual auscultatory measurement, the observer determines the inflation limit by turning a dial (100-280 mm Hg) and selecting one of the three deflation speeds: 2.5, 4.5 and 6.5 mm Hg s À1 . Alternatively, automated oscillometric measurement can be selected through a flick of a switch, and a reading obtained in this manner is stored in the device memory. The device has a convenient fixed desk stand with a cuff holder that accommodates both standard (22-32 cm) and large (32-42 cm) cuffs. The dimensions of the model are 136 (width) Â 206 (length) Â 276 mm 3 (height) and it weighs 1000 g (including the cuff container). It is powered by an alternating current adapter and a 4.8-V rechargeable battery pack, which has a 4-h charge time with an LED (light-emitting diode) display to show the battery charge status.
In this study, we validated the manual and oscillometric measurement modes of the device and also developed and validated an accurate blinded mode according to the European Society of Hypertension (ESH) International Protocol. 15 
Materials and methods
Ethical approval and participant recruitment Ethical approval for the study was obtained. Observers were trained in the correct BP measurement technique (either by being familiar with the validation procedure or by making use of the training provided in the British Hypertension Society website) 16 and familiarized themselves with using the equipment before recruiting participants to the study. Participants included staff and patients recruited from Guy's and St Thomas' Hospitals (London, UK), Dulwich Community Hospital (London, UK) and Kimberley Hospital Complex (Kimberley, South Africa). Written informed consent was obtained from all participants. Exclusion criteria included the presence of a sustained arrhythmia or unclear Korotkoff sounds.
BP measurements were taken in a quiet room at room temperature. Participants were asked to rest for 5-10 min, during which demographic data were recorded and their approximate mid-arm circumference was measured. A standard (22-32 cm) or large cuff (32-42 cm) was chosen depending on arm circumference.
Validation procedure and analysis
The ESH protocol has two phases to pass before validation is complete. Phase one requires five participants in each BP category, for systolic BP (SBP) (90-129, 130-160 and 161-180 mm Hg) and diastolic BP (DBP) (40-79, 80-100 and 101-130 mm Hg). On successful achievement of the phase 1 accuracy criteria (Table 1) , recruiting continues until 11 participants are allocated to each category, totalling 33 participants.
Using a 3-M Littman Classic II teaching stethoscope, nine sequential same-arm BP measurements were taken by trained observers alternating between simultaneous mercury sphygmomanometer readings and the device. To facilitate an additional simultaneous data recording (for secondary data analysis), both mercury sphygmomanometers and the device were connected in parallel. There was at least a 30-s break between each measurement to prevent venous congestion, but no longer than 60 s to limit variability between BP readings.
The mean of the first BP reading by the observers (entry BP) was used to categorize the participant into one of the three BP ranges stated above. The second BP measurement (test device reading) was only confirmatory and not used in the analysis. The latter seven measurements were analysed using Microsoft Excel (Microsoft, Washington, USA). The absolute difference between the device reading and the mean of the observers' readings before and after were calculated. The smallest absolute difference for each pair was chosen resulting in a total of three differences for each participant and these were classified into three categories (within 5, 10 and 15 mm Hg) for SBP and DBP, respectively. Phases 1 and 2.1 of the ESH protocol evaluated overall device accuracy, and the device had to comply with the minimum requirements of the protocol (Table 1) . Phase 2.2 of the protocol evaluated the accuracy of the device for individual participants by analysing the number of differences per participant within 5 mm Hg.
The development and validation of the different measurement modes are graphically summarized in Figure 1 and described below.
Manual auscultatory mode
Validation of the auscultatory mode of the Nissei DM-3000 was performed according to the abovedescribed methodology, with the deflation rate of the device set to 2.5, 4.5 and 6.5 mm Hg s À1 , respectively, for each separate study. All ESH protocol requirements were fulfilled for the 2.5 mm Hg s À1 study, and data obtained from 33 Abbreviation: ESH, European Society of Hypertension.
Validation of Nissei DM-3000participants were analysed. Subsequently, 10 patients were recruited to each of the remaining two studies (4.5 and 6.5 mm Hg s À1 deflation rates). In all, 20 BP measurements were taken in each of these participants alternating between mercury sphygmomanometry by trained observers and the device. This resulted in a set of 10 differences per participant (100 differences in total) that were analysed according to the ESH guidelines, which require a set of 99 differences.
Automated oscillometric mode
Both validation studies of the oscillometric mode (before and after device modification to improve accuracy) were conducted according to the ESH protocol methodology described above, with data obtained from 33 participants analysed for each study.
Blinded mode
This measurement mode was developed in collaboration with the manufacturer and is not a standard feature of the current Nissei DM-3000 device. The deflation speed of the device was set at 2.5 mm Hg s À1 in this mode. The observer selected the appropriate cuff inflation limit and initiated cuff inflation by pressing the start button. The LED display initially lit up (similar to a mercury column), but disappeared on cuff deflation. The observer pressed a button as soon as Korotkoff sounds (K1 for SBP) were identified and again when they disappeared (K5 for DBP). Observers were encouraged to ensure that they were confident of Korotkoff sounds before pressing the button. The button could only be pressed twice during cuff deflation: once to identify SBP and once to identify DBP, followed by rapid cuff deflation. Subsequently, the LED display would highlight the area between the identified SBP and DBP on the graduated column display, which the observer then had to read to record the measurement. No numeric measurement data were displayed on the LCD.
The development of an accurate blinded mode required three separate validation studies. Modifications to this measurement mode involved defining the duration of recognition time and reaction time. Recognition time was defined as the time required for the observer to distinguish between true repetitive Korotkoff sounds and artefact noise. Reaction time was defined as the time from K-sound recognition to pressing the device button. Whereas reaction time was typically split seconds, recognition time was dependent on each participant with regard to pulse rate, clarity of Korotkoff sounds, etc.
After the initial results of the first two studies, modifications were made to the correction factor that was incorporated for SBP and DBP, respectively, for the blinded mode only. This is detailed in the 'Results' section. The final study was conducted according to the ESH protocol methodology as described above and included 33 participants.
Results
Manual auscultatory mode (2.5 mm Hg s À1 deflation rate) A total of 39 participants were recruited to the study. The first 33 participants to fulfil the ESH protocol criteria were selected for analysis. The same participants were included for both SBP and DBP analysis. Demographics of the study population are shown in Table 2 . One participant had SBP values exceeding the 180 mm Hg limit of the protocol.
The manual measurement mode of the Nissei DM-3000 device passed all phases of the ESH protocol (Table 3) , with a deflation rate of 2.5 mm Hg s À1 . It achieved a mean difference ± s.d. of À0.6 ± 4.4 and À1.4 ± 2.8 mm Hg for SBP and DBP, respectively, which is well within the acceptable range specified by the Association for the Advancement of Medical Instrumentation (AAMI). 17 Figures 2 and 3 show the mean-against-difference plots 18 of the data for sequential comparison. All inter-observer differences were o5 mm Hg.
An additional simultaneous comparison was made and the device achieved a mean difference± s.d. of À1.8 ± 1.9 for SBP and À2.4 ± 2.3 mm Hg for DBP, also within the AAMI standard. Table 2) .
The Nissei DM-3000 device met the AAMI criteria for both deflation speeds ( 
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show the mean-against-difference plots of the data for sequential comparison.
In an additional simultaneous comparison, the device achieved a mean difference ± s.d. of À2.6±3.3 and À3.0±3.1 mm Hg for SBP and DBP, respectively (4.5 mm Hg s À1 study), and À3.7±2.5
and À3.8 ± 3.3 mm Hg for SBP and DBP, respectively, in the 6.5 mm Hg s À1 study. All inter-observer differences were o5 mm Hg for the 4.5 mm Hg s À1 study, and only one inter-observer difference in the 6.5 mm Hg s À1 study was 45 mm Hg with a recorded difference of 6 mm Hg.
Automated oscillometric mode
In the initial study, 40 participants were recruited of whom the first 33 to fulfil the ESH protocol requirements were selected for analysis. Four participants had a SBP exceeding the high category limit of 180 mm Hg, with the highest recorded pressure being 224 mm Hg.
The device met all the criteria of phases 1 and 2.1 of the ESH protocol, but failed phase 2.2 for SBP with only 20 participants (instead of the minimum requirement of 22 participants) having at least 2 out of their 3 differences within 5 mm Hg. However, it did achieve a mean difference ± s.d. of 2.7 ± 6.8 mm Hg for SBP and 3.4 ± 7.1 mm Hg for DBP, which was within the AAMI recommendations. All interobserver differences were o5 mm Hg.
The device was returned to the manufacturer for minor algorithm adjustments to improve the s.d., with the view to improving intra-participant accuracy. Subsequently, the device was revalidated according to the ESH protocol.
A total of 45 patients were recruited and the first 33 participants to fulfil the ESH protocol criteria for SBP and DBP, respectively, were selected for analysis. Both systolic and diastolic values were analysed in 24 subjects, whereas only systolic or diastolic values were analysed in 18 other subjects (9 each for systolic or diastolic). Demographic data of the study group are shown in Table 2 .
The Nissei DM-3000 device passed all phases of the ESH protocol (Table 3 ). The device also achieved an improved mean difference±s.d. of À0.8±6.0 and 0.8 ± 4.8 mm Hg for SBP and DBP, respectively. Figure 4 shows a mean-against-difference plot of the data. All inter-observer differences were o5 mm Hg. À1.4 ± 2.8 -1.9 ± 3.3 À2.0 ± 3.5
Abbreviation: BP, blood pressure. 
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Blinded mode In the first study, 17 participants were recruited, and initial data analysis yielded a mean difference ± s.d. of À1.6 ± 3.6 (SBP) and À4.2 ± 4.2 mm Hg (DBP) for sequential measurement comparisons according to the ESH protocol. An additional simultaneous measurement comparison was made and the device achieved À1.7±2.5 (SBP) and À6.2±2.5 mm Hg (DBP).
After slight modifications to the correction factor, nine participants were recruited and BP measurements were performed and analysed according to the ESH protocol. The results were acceptable for SBP, but not for DBP with a marginally improved mean difference±s.d. of À0.7±2.5 (SBP) and À4.0 ± 3.1 mm Hg (DBP) for sequential comparison and À2.9 ± 2.2 (SBP) and À5.2 ± 1.5 mm Hg (DBP) for simultaneous comparison.
As the correction factor was proportionately related to heart rate and based on correcting for two noiseless beats for DBP measurement, this was adjusted to only 1 noiseless beat. Subsequently, 33 participants were recruited. Five participants fulfilled requirements of the high range (4160/ 100 mm Hg). Demographic data are shown in Table 2 . One participant had a SBP exceeding the 180 mm Hg limit of the protocol, with the highest SBP recorded being 218 mm Hg.
The device passed all phases of the ESH protocol (Table 3 ). In addition, it also achieved a markedly improved mean difference±s.d. of À0.1±2.6 (SBP) and 0.04 ± 2.4 mm Hg (DBP) for sequential comparison and 1.0 ± 3.2 (SBP) and 0.2 ± 2.4 mm Hg (DBP) for simultaneous comparison. Figure 5 shows a mean-against-difference plot of the data. All interobserver differences were o5 mm Hg.
Discussion
In this study, we validated the manual and oscillometric measurement modes of the Nissei DM-3000 device and developed and validated an additional blinded mode. All of the measurement modes met the criteria of the ESH protocol and achieved a mean difference±s.d. that are within the standards required by AAMI; therefore, this device is a suitable alternative to the mercury sphygmomanometer in an adult population.
Minor amendments to the ESH protocol are noted. First, we included participants whose SBP exceeded the high range of the protocol (that is, 4180 mm Hg), as paradoxically it was extremely difficult to find subjects with SBP between 160 and 180 mm Hg in a timely manner. In none of the studies could this be identified as likely to have influenced the outcome, especially in the manual measurement modes. This amendment would only bias against the device and as it still passes, it supports its accuracy.
Second, we only recruited 10 participants for validation of the manual measurement mode's 4.5 and 6.5 mm Hg s À1 deflation rates and performed a series of 20 measurements on each to achieve a total set of 100 differences, which is similar to the ESH protocol requirement of 99 differences. Despite not fulfilling the pressure range specification of the protocol, we do not believe this to have influenced the outcome as measurement accuracy was based on auscultation by the observer, with no oscillometric involvement. In addition, we have shown the initial validation to be successful, and therefore believe that completing the entire protocol so many times to check minor variations would be a prohibitive expense and scientifically unnecessary.
It is interesting to note that the device fulfils the ESH criteria for deflations speeds above the recommended 2-3 mm Hg s À1 . 1 However, not surprisingly, the deflation rate of 2.5 mm s À1 was found to be most accurate for SBP, as it has previously been shown that faster deflation rates are likely to underestimate SBP. 19 One possible advantage in selecting a different deflation rate relates to the suggestion that measurement accuracy at a set deflation rate is influenced by heart rate. One study found that a standard deflation rate of 3 mm Hg s À1 resulted in a maximum error of 2.5 mm Hg for both SBP and DBP at a heart rate of 72 beats per min. This error increased to 44 mm Hg at 40 beats per min, and therefore the authors recommend a cuff deflation rate of 2 mm Hg per beat rather than 2 mm Hg s À1 to minimize measurement errors. 20 Unlike other hybrid devices, [11] [12] [13] [14] the Nissei DM-3000 offers a set deflation rate, which may contribute to more accurate BP measurements compared with human deflation, as the latter may not deflate reliably at a fixed rate.
There is great clinical benefit in having one device that enables both a manual auscultatory and automated oscillometric BP measurement. The automated mode provides an alternative to auscultation when Korotkoff sounds are poor and eliminates terminal digital preference and observer bias, as well as the error incurred with rapid manual deflation rates. 1 However, as severe accuracy limitations have been shown with oscillometric BP Validation of Nissei DM-3000measurement in certain sub-populations, 5-8 these participants would benefit from the manual measurement mode of this device.
The blinded measurement mode is a feature of devices such as the PMS Mandhaus 14 and A&D UM-101, 12 and although it has been reported to underestimate BP, we recognized the clinical benefit that such a measurement mode could offer.
We therefore developed and validated a blinded measurement mode to the Nissei DM-3000 by defining not only recognition time but also reaction time and adjusting the correction factor that is added to the observer indication of SBP and DBP before the final BP display. The blinded BP measurement mode was the most accurate measurement mode of this device, and although this is not a standard feature of the Nissei DM-3000 it has been incorporated into similar models (such as DM-1000 and DM-500) that are currently undergoing validation.
Although reaction time has been shown to increase with age 21 and may therefore influence accuracy, we have shown that recognition time has a far greater influence and that the error of reaction time is negligible by current protocol requirements.
The Nissei DM-3000 device is supplied with a standard and large cuff and although a wider cuff selection is available for use with other Nissei models, their accuracy in this device will need further investigation.
Hybrid devices such as the Nissei DM-3000 ( Figure 6 ) are a suitable replacement to the mercury sphygmomanometer, particularly for patients with conditions such as arrhythmias and pre-eclampsia, where the use of automated devices are generally precluded. Figure 6 The Nissei DM-3000.
What is known about this topic K Only blood pressure (BP) devices that have passed the criteria of recognized validation protocols should be recommended for clinical use. K Hybrid devices combine both automated (oscillometric) and auscultatory (manual) features in a mercury-free device. K The blinded measurement mode in current hybrid devices is not recommended for clinical use because of underestimation of BP.
What this study adds K This study reports on the development and validation of an accurate blinded measurement mode to the Nissei DM-3000 device by defining recognition and reaction time. K Manual auscultatory device accuracy is shown at deflation speeds between 2.5 and 6.5 mmHg s À1 according to the International Protocol of the European Hypertension Society. K Automated oscillometric BP measurement is shown accurately in this hybrid device that enables both manual and automated BP measurements.
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